Research synthesis only; not medical advice. No material sold as “research use only” should be assumed safe, sterile, authentic, or suitable for human use. Testing requires validated methods, representative samples, reference standards, specifications, and qualified interpretation.
Pharmaceutical quality attributes
Product quality is multidimensional. Identity, amount, purity, uniformity, sterility, endotoxin control, particles, pH, osmolality, and container performance answer different questions.
| Attribute | Meaning | How it is evaluated / product-specific qualification |
|---|---|---|
| Identity | Whether the substance is the stated peptide | Orthogonal comparison with suitable reference material, such as chromatographic and mass-spectrometric evidence |
| Assay / potency | Amount or biological activity relative to the claim | Product-suitable quantitative or functional assay and validated specification |
| Purity | Related substances, degradation products, and process impurities | One or more separation methods with product-specific reporting and acceptance criteria |
| Content uniformity | Consistency between dosage units | Applicable compendial or approved-product method and sampling plan |
| Sterility | Absence of viable microorganisms within the validated assurance system | Manufacturing controls plus applicable sterility testing; a sampled test does not create sterility |
| Bacterial endotoxins | Control of pyrogenic Gram-negative bacterial material | Product- and route-specific limit with a suitable compendial method |
| Particulate matter | Visible and subvisible particle control | Applicable product-class and compendial methods with defined size ranges |
| pH | Acidity or alkalinity within a validated range | Product specification and calibrated method |
| Osmolality | Solute-particle concentration relevant to the formulation and route | Product-specific specification and suitable measurement |
Passing one attribute does not imply that another passed. A purity result, for example, does not by itself establish identity, sterility, potency, or endotoxin control.
Product quality connects separately to identity, assay, purity, uniformity, sterility, endotoxins, particles, and container or closure. Passing one test does not imply the others passed.
How attributes are tested
USP tests
Editions and product requirements must be checked; citing a chapter does not prove that a sampled product passed.
| Standard | Test domain | Scope caveat |
|---|---|---|
USP <71> | Sterility tests | Sampling and method limits apply within a broader sterility-assurance system |
USP <85> | Bacterial endotoxins | Product- and route-specific limits and method suitability are required |
USP <151> | Pyrogen test | Does not collapse all pyrogen and endotoxin questions into one result |
USP <787> / <788> / <790> | Subvisible and visible particles | Applicable chapter depends on product class and particle domain |
USP <795> / <797> | Compounding frameworks | These are professional standards, not evidence that a commercial material passed testing |
USP <905> | Uniformity of dosage units | Applies within its defined dosage-unit scope |
USP <1151> | Pharmaceutical dosage forms | General dosage-form concepts do not establish product conformance |
Ph. Eur. chapters
Editions and product requirements must be checked; a chapter reference is not a certificate of conformity.
| Standard | Test domain | Scope caveat |
|---|---|---|
| Ph. Eur. 2.6.1 | Sterility | A sampled test is one part of the assurance system |
| Ph. Eur. 2.6.14 | Bacterial endotoxins | Method suitability and product limit remain necessary |
| Ph. Eur. 2.6.30 | Monocyte-activation test | Addresses a defined pyrogen-testing domain |
| Ph. Eur. 2.9.40 | Uniformity of dosage units | Applies only within the chapter’s scope |
| Ph. Eur. 2034 | Fermentation products / ribosomal peptides | A monograph’s applicability must be established for the product |
What a result can establish
A result applies to the sampled material, the method, the reference, the time point, and the reported uncertainty. It does not automatically transfer to other units, lots, vendors, or later time points. End-user visual inspection cannot reveal subtle chemical degradation, amount discrepancy, sterility, or endotoxin control.
Authenticity and counterfeit detection
Counterfeit or substandard risk can involve wrong identity, amount, impurity profile, packaging, manufacturer claim, or supply-chain history. Surveillance laboratories may use chromatography, mass spectrometry, NMR, vibrational spectroscopy, diffraction, or product-suitable functional methods.
Source context: Hall and Newton’s 2004 literature review documents substandard and counterfeit medicine problems across reported settings. It establishes the existence and types of risk, not a current prevalence estimate for peptide products.
Method access alone is insufficient. Sample provenance, chain of custody, method suitability, qualified reference material, validated specifications, and uncertainty define the scope of any conclusion. An unknown chain of custody or an unsuitable method breaks the inference from result to product claim.
Seller or package claim → sample provenance → method suitability → reference standard → result and uncertainty → scope-limited conclusion. Unknown chain of custody or an unsuitable method breaks the inference.
Packaging as part of quality
Container-closure system
Glass, elastomeric stoppers, seals, polymers, coatings, and integrated devices can protect the product or interact with it. Container-closure integrity, adsorption, delamination, permeability, and compatibility therefore form part of product quality.
Leachables and extractables
Extractables are substances forced from packaging materials under laboratory study conditions; leachables are substances observed in the product under relevant conditions. Controlled extraction, product leachable studies, and toxicological assessment address different parts of that evidence chain.
See sterility and contamination risk, lyophilization and stability, identity and structure assets, and cross-border online supply.
Sources
USP–NF. Rockville, MD: United States Pharmacopeia; 2026. Chapters:
<71>,<85>,<151>,<787>,<788>,<790>,<795>,<797>,<905>,<1151>.European Pharmacopoeia 11th ed. Strasbourg: EDQM; 2026. Chapters: 2.6.1, 2.6.14, 2.6.30, 2.9.40.
FDA. Guidance for Industry: Container and Closure System Integrity Testing in Lieu of Sterility Testing as a Component of the Stability Protocol for Sterile Products. 2008.
FDA. Guidance for Industry: Chemistry, Manufacturing, and Controls (CMC) Information for Certain Recombinant Therapeutic Products. 2004. https://www.fda.gov/media/72414/download
EMA. Guideline on the Pharmaceutical Quality of Inhalation and Nasal Products. EMA/CHMP/QWP/49313/2005. 2006. https://www.ema.europa.eu/en/pharmaceutical-quality-inhalation-nasal-products-scientific-guideline
FDA. Guidance for Industry: Pyrogen and Endotoxins Testing: Questions and Answers. 2012. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pyrogen-and-endotoxins-testing-questions-and-answers
World Health Organization. WHO guidelines on good manufacturing practices for the manufacture of pharmaceutical products containing biological active substances. WHO Technical Report Series, No. 1020, Annex 3. 2020.
Hall KA, Newton PN. Substandard and counterfeit medicines: a review of the literature. Trop Med Int Health. 2004;9(1):116–130. https://doi.org/10.1046/j.1365-3156.2003.01162.x